07May
03May
TetraGenetics Appoints Alison Taunton-Rigby, Ellen Baron and Daniel Grau to its Board of Directors
TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced today the addition of three new board members: Alison Taunton-Rigby Ph.D., OBE, Ellen Baron Ph.D. and Daniel Grau M. Phil. Read more >>
03May
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc. today announced the completion of subject enrollment in RESOLVE-1, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of systemic sclerosis (SSc). The Company expects to report topline results from this study in the summer of 2020. These data are anticipated to support an initial marketing application for lenabasum. Read more >>
02May
Myomo® Announces New Distribution Agreement for Australia / New Zealand
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New Zealand. Read more >>
02May
Carbonite Exhibits Data Protection Platform at Dell Technologies World 2019
Carbonite, Inc., a leader in cloud-based data protection, will showcase the Carbonite Data Protection Platform at Dell Technologies World, April 29th – May 2nd 2019 in Las Vegas, Nevada. Read more >>
01May